Brentuximab vedotin: Phase I started

Seattle Genetics and Takeda's Millennium Pharmaceuticals Inc. subsidiary began a open-label, dose-escalation, North American Phase I trial in 40 patients to evaluate brentuximab plus Adriamycin doxor...